1
Clinical Trials associated with OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd)Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
100 Clinical Results associated with OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd)
100 Translational Medicine associated with OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd)
100 Patents (Medical) associated with OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd)
100 Deals associated with OmniMSC-AMI(Taiwan Bio Therapeutics Co., Ltd)